Bellerophon Therapeutics Inc
OTC:BLPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bellerophon Therapeutics Inc
OTC:BLPH
|
US |
|
CVR Energy Inc
NYSE:CVI
|
US |
|
SDI Ltd
ASX:SDI
|
AU |
|
3i Infotech Ltd
NSE:3IINFOLTD
|
IN |
|
Getty Images Holdings Inc
NYSE:GETY
|
US |
|
N
|
Ningbo Fujia Industrial Co Ltd
SSE:603219
|
CN |
|
Chengdu Expressway Co Ltd
HKEX:1785
|
CN |
|
3
|
3M Co
F:MMM
|
US |
|
A
|
Atalaya Mining PLC
LSE:ATYM
|
CY |
|
VisasQ Inc
TSE:4490
|
JP |
|
Bawan Company SJSC
SAU:1302
|
SA |
|
Tongcheng Travel Holdings Ltd
HKEX:780
|
CN |
|
Marimekko Oyj
OTC:MKKOF
|
FI |
|
Zurich Insurance Group AG
LSE:0QP2
|
CH |
|
Beauty Garage Inc
TSE:3180
|
JP |
Bellerophon Therapeutics Inc
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.
